Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease.
Gonzalez-Cordon A, Assoumou L, Camafort M, Domenech M, Guaraldi G, Domingo P, Rusconi S, Raffi F, Katlama C, Masia M, Bernardino JI, Saumoy M, Pozniak A, Gatell JM, Martinez E; NEAT022 Study Group. Gonzalez-Cordon A, et al. J Antimicrob Chemother. 2020 Nov 1;75(11):3334-3343. doi: 10.1093/jac/dkaa292. J Antimicrob Chemother. 2020. PMID: 32737482 Clinical Trial.
Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study.
Saumoy M, Ordóñez-Llanos J, Martínez E, Ferrer E, Domingo P, Ribera E, Negredo E, Curto J, Sánchez-Quesada JL, Di Yacovo S, González-Cordón A, Podzamczer D. Saumoy M, et al. J Antimicrob Chemother. 2015 Apr;70(4):1130-8. doi: 10.1093/jac/dku501. Epub 2014 Dec 23. J Antimicrob Chemother. 2015. PMID: 25538166 Clinical Trial.
Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression.
Rojas J, Blanco JL, Marcos MA, Lonca M, Tricas A, Moreno L, Gonzalez-Cordon A, Torres B, Mallolas J, Garcia F, Gatell JM, Martinez E. Rojas J, et al. J Antimicrob Chemother. 2016 Jul;71(7):1975-81. doi: 10.1093/jac/dkw078. Epub 2016 Mar 28. J Antimicrob Chemother. 2016. PMID: 27021341 Free article.
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT022 Study Group. González-Cordón A, et al. J Antimicrob Chemother. 2021 Aug 12;76(9):2380-2393. doi: 10.1093/jac/dkab158. J Antimicrob Chemother. 2021. PMID: 34120186 Clinical Trial.
Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study.
Saumoy M, Sánchez-Quesada JL, Assoumou L, Gatell JM, González-Cordón A, Guaraldi G, Domingo P, Giacomelli A, Connault J, Katlama C, Masiá M, Ordónez-Llanos J, Pozniak A, Martínez E, Podzamczer D. Saumoy M, et al. J Antimicrob Chemother. 2022 Jun 29;77(7):1980-1988. doi: 10.1093/jac/dkac117. J Antimicrob Chemother. 2022. PMID: 35411401 Clinical Trial.
Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial.
Waters L, Assoumou L, González-Cordón A, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masiá M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell JM, Pozniak A, Martínez E; NEAT 022 Study Group. Waters L, et al. Clin Infect Dis. 2023 Mar 4;76(5):861-870. doi: 10.1093/cid/ciac827. Clin Infect Dis. 2023. PMID: 36259527 Clinical Trial.
Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial.
Martinez E, Gonzalez-Cordon A, Ferrer E, Domingo P, Negredo E, Gutierrez F, Portilla J, Curran A, Podzamczer D, Ribera E, Murillas J, Bernardino JI, Santos I, Carton JA, Peraire J, Pich J, Deulofeu R, Perez I, Gatell JM; ATADAR Study Group. Martinez E, et al. Clin Infect Dis. 2015 Mar 1;60(5):811-20. doi: 10.1093/cid/ciu898. Epub 2014 Nov 10. Clin Infect Dis. 2015. PMID: 25389256 Free article. Clinical Trial.
Tolerability of integrase inhibitors in a real-life setting.
Peñafiel J, de Lazzari E, Padilla M, Rojas J, Gonzalez-Cordon A, Blanco JL, Blanch J, Marcos MA, Lonca M, Martinez-Rebollar M, Laguno M, Tricas A, Rodriguez A, Mallolas J, Gatell JM, Martinez E. Peñafiel J, et al. J Antimicrob Chemother. 2017 Jun 1;72(6):1752-1759. doi: 10.1093/jac/dkx053. J Antimicrob Chemother. 2017. PMID: 28333231
89 results